Select Language

Cytokine Targets

https://doi.org/10.1186/s12943-020-01294-3
Cytokines establish a conducive microenvironment for eventual tumor metastasis

Cytokines are a class of small molecule proteins or polypeptides that are stimulated, synthesized or secreted by immune cells (such as monocytes, macrophages, T cells, B cells, NK cells, etc.) and some non-immune cells (endothelial cells, epidermal cells, fibers mother cells, etc.). Cytokines can transmit information between cells. Cytokines have immune regulation and effector functions including the regulation of innate immunity, adaptive immunity, hematopoiesis, repair of damaged tissues, cell growth, and differentiation. Cytokines play an important role in the immune system by regulating the intensity and duration of immune responses.

Many cytokines promote or restrict each other in vivo, forming an extremely complex immune regulatory network. Specific cytokines exert their biological effects in autocrine, paracrine or endocrine modes, and have various properties such as pleiotropic, overlapping, antagonistic and synergistic. However, under certain conditions, cytokines can also participate in the occurrence of various diseases, and even trigger cytokine storm and cytokine storm syndrome, resulting in multiple organ damage, functional failure and death. Complex and dynamic interactions between cytokines and their receptors mediate chronic inflammation and immunosuppressive tumor microenvironment (TME) leading tumor progression, metastasis, and reduced response to therapy. Autoimmune diseases are the second largest therapeutic field after tumors. Cytokines are the final effector proteins, blocking their function can effectively relieve tissue damage and inflammation in autoimmune diseases. With the improvement of biopharmaceutical technology, there is a huge growth space for targeted cytokine drugs in the future, which is a promising prospect for the treatment of tumors and autoimmune diseases.

ACROBiosystems is adhering to the philosophy of "Better Biologics for Better Life", and has been deeply involved in the field of recombinant proteins for many years. We have developed a series of recombinant cytokines and their receptor proteins including Interleukins, Growth Factors, Tumor Necrosis Factors (TNFs), Chemokines, Colony-Stimulating Factors (CSFs), Interferons (IFNs), Complement Factors, etc., to meet your drug development needs and create a new chapter in cytokine-targeted drug development with you.

Product Features

Closer to the natural conformation in humans due to expressed by HEK293 cells (Human Embryonic Kidney cells)

Biotinylated cytokines are exclusively produced using Avitag™ site-specific biotinylation technology: the biotinylation only happens on the lysine residue of Avi tag; no interference with the target protein's natural binding activities; the protein orientation is uniform when immobilized on an avidin-coated surface

High purity and homogeneity in structure are verified by both SDS-PAGE and SEC-MALS

High bioactivity of binding with receptor or antibody is verified by ELISA/SPR/BLI/cell-based assay. Protocols shared

Strict quality control to guarantee high batch-to-batch consistency (ELISA as QC test)

Various species coverage, suitable for species cross experiments: Human, Mouse, Rat, Cynomolgus, Rhesus Macaque, Rabbit, Canine…

Various labels and tags design

More comprehensive cytokine products, hot cytokine targets are available

Hot Cytokines

IL-2 and IL-2 Receptors Patented Technology IL-4 and IL-4R IL-6 and IL-6R IL-23A&IL-12B IL-15 VEGF TGF-beta FGF TNF-alpha GDF-15 CSF EGF and EGFR IGF-I R IFN Complement C3 Complement C5

Verification Data

High purity and homogeneity in structure verified by SDS-PAGE and SEC-MALS

Human IL-2RB&IL-2RG Heterodimer Protein, Fc Tag&Fc Tag (MALS verified) (Cat. No. ILG-H5254) on SDS-PAGE under reducing condition. The purity of the protein is greater than 95%. As verified by SEC-MALS, the purity is more than 90% and the molecular weight of this protein is around 140-160 kDa.

Biotinylated Human TGFBR2, Fc,Avitag (Cat. No. TG2-H82F6) on SDS-PAGE under reducing condition. The purity of the protein is greater than 95%. As verified by SEC-MALS, the purity is more than 90% and the molecular weight of this protein is around 110-125 kDa.

Biotinylated Human TNF-alpha, His,Avitag (active trimer) (MALS verified) (Cat. No. TNA-H82E3) on SDS-PAGE under reducing condition. The purity of the protein is greater than 95%. As verified by SEC-MALS, the purity is more than 90% and the molecular weight of this protein is around 55-70 kDa.

Human GDF-15, Fc Tag (Cat. No. GD5-H5269) on SDS-PAGE under reducing and non-reducing conditions. The purity of the protein is greater than 95%. As verified by SEC-MALS, the purity is more than 90% and the molecular weight of this protein is around 74-100 kDa.

High bioactivity verified by ELISA (QC tested)

Immobilized Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TGF-Beta 1, Avitag (Cat. No. TG1-H8217) with a linear range of 0.1-3 ng/mL (QC tested).

Protocol

Immobilized Human M-CSF R, Fc Tag (Cat. No. CSR-H5258) at 2 μg/mL (100 μL/well) can bind Biotinylated Human M-CSF, His,Avitag (Cat. No. MCF-H82E6) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

Immobilized Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) at 0.1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB Ligand, Fc, Avitag (Cat. No. 41L-H82F9) with a linear range of 0.4-6 ng/mL (QC tested).

Protocol

Immobilized Cetuximab at 2 μg/mL (100 μL/well) can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with a linear range of 0.006-0.025 μg/mL (QC tested).

Protocol

Immobilized Human Complement C5, His Tag (Cat. No. CO5-H52Ha) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.2-3 ng/mL (QC tested).

Protocol

Affinity verified by SPR/BLI

Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay (Biacore T200).

Protocol

Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) captured on CM5 chip via anti-His antibody, can bind Human IL-15, premium grade (Cat. No. IL5-H4117) with an affinity constant of 21.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

Loaded Anti-IL23A & IL12B MAb (P40 domain) on Protein A Biosensor, can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 1.07 nM as determined in BLI assay (ForteBio Octet Red96e).

Protocol

Loaded Anti-IL23A & IL12B MAb (P40 domain) on Protein A Biosensor, can bind Human IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (Cat. No. ILB-H52W5) with an affinity constant of 0.588 nM as determined in BLI assay (ForteBio Octet Red96e).

Protocol

High batch-to-batch consistency

Affinity of three different lots of Human IL23A & IL12B, His Tag protein (Cat. No. ILB-H52W5) is verified by binding with Human IL-23R, and the result shows very high batch-to-batch consistency. (BLI)